Financing ·
Zentalis Pharmaceuticals entered into an underwriting agreement to sell 23,000,000 shares of common stock at $3.50 per…
ZNTLZentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals entered into an underwriting agreement to sell 23,000,000 shares of common stock at $3.50 per share, with a 30-day option for the underwriters to purchase up to 3,450,000 additional shares. The company estimates net proceeds of approximately $75.1 million after deducting discounts and expenses. Closing is expected on August 17, 2026. Proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, and general corporate purposes. Zentalis Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing treatments for inflammatory diseases.